Tags

Type your tag names separated by a space and hit enter

The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis.
Maturitas 2005; 51(3):246-53M

Abstract

OBJECTIVES

A double-blind, randomized, placebo-controlled trial was conducted in women with postmenopausal osteoporosis to evaluate effects on biochemical markers and urinary excretion of zinc (Zn) of calcitonin therapy.

METHODS

Patients were required to have a bone mineral density (BMD) of 2.5 S.D. or more below the young adult mean either at the postero-anterior lumbar spine or at the femoral neck. Subjects were eligible for our study if they were 50 years or older, with at least 5 years of menopause, and in good general health as determined by medical history and a routine clinical blood analysis. The patients were randomly assigned to receive intranasal salmon calcitonin (200 IU/day; 50 patients) or placebo (50 patients). All patients received supplemental calcium (1000 mg/day). Additionally, 40 age-matched, demographically similar, healthy postmenopausal women were also selected as controls. Measurements of cross-linked N-telopeptides of type I collagen (uNTx), osteocalcin (sOC), and urinary zinc concentration were done. All parameters were measured before therapy and again after 1, 3 and 6 months.

RESULTS

After 3 and 6 months of treatment, a higher decrease of most indices was observed in the calcitonin group. A statistically significant decrease occurred in the levels of sOC, uNTx and uZn after 3 and 6 months in patients receiving calcitonin therapy (P<0.05). Levels of sOC and uNTx in calcitonin group were significantly different after 3 and 6 months from both placebo and baseline values of calcitonin group (P<0.05). Levels of sOC, uNTx and uZn decreased about 40, 46 and 37%, respectively, in calcitonin group at 6 months after the start of treatment.

CONCLUSIONS

Our study suggests that values of uNTx, uZn and sOC were significantly lower in the patient group than those in control group and in postmenopausal women with osteopororsis, calcitonin reduces the concentrations of uNTx, uZn and sOC.

Authors+Show Affiliations

Department of Biochemistry, Medical Faculty of Dicle University, Diyarbakir, Turkey.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

15978968

Citation

Colpan, Leyla, et al. "The Effect of Calcitonin On Biochemical Markers and Zinc Excretion in Postmenopausal Osteoporosis." Maturitas, vol. 51, no. 3, 2005, pp. 246-53.
Colpan L, Gur A, Cevik R, et al. The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis. Maturitas. 2005;51(3):246-53.
Colpan, L., Gur, A., Cevik, R., Nas, K., & Sarac, A. J. (2005). The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis. Maturitas, 51(3), pp. 246-53.
Colpan L, et al. The Effect of Calcitonin On Biochemical Markers and Zinc Excretion in Postmenopausal Osteoporosis. Maturitas. 2005 Jul 16;51(3):246-53. PubMed PMID: 15978968.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - The effect of calcitonin on biochemical markers and zinc excretion in postmenopausal osteoporosis. AU - Colpan,Leyla, AU - Gur,Ali, AU - Cevik,Remzi, AU - Nas,Kemal, AU - Sarac,Aysegul Jale, PY - 2004/01/01/received PY - 2004/07/26/revised PY - 2004/07/27/accepted PY - 2005/6/28/pubmed PY - 2006/1/6/medline PY - 2005/6/28/entrez SP - 246 EP - 53 JF - Maturitas JO - Maturitas VL - 51 IS - 3 N2 - OBJECTIVES: A double-blind, randomized, placebo-controlled trial was conducted in women with postmenopausal osteoporosis to evaluate effects on biochemical markers and urinary excretion of zinc (Zn) of calcitonin therapy. METHODS: Patients were required to have a bone mineral density (BMD) of 2.5 S.D. or more below the young adult mean either at the postero-anterior lumbar spine or at the femoral neck. Subjects were eligible for our study if they were 50 years or older, with at least 5 years of menopause, and in good general health as determined by medical history and a routine clinical blood analysis. The patients were randomly assigned to receive intranasal salmon calcitonin (200 IU/day; 50 patients) or placebo (50 patients). All patients received supplemental calcium (1000 mg/day). Additionally, 40 age-matched, demographically similar, healthy postmenopausal women were also selected as controls. Measurements of cross-linked N-telopeptides of type I collagen (uNTx), osteocalcin (sOC), and urinary zinc concentration were done. All parameters were measured before therapy and again after 1, 3 and 6 months. RESULTS: After 3 and 6 months of treatment, a higher decrease of most indices was observed in the calcitonin group. A statistically significant decrease occurred in the levels of sOC, uNTx and uZn after 3 and 6 months in patients receiving calcitonin therapy (P<0.05). Levels of sOC and uNTx in calcitonin group were significantly different after 3 and 6 months from both placebo and baseline values of calcitonin group (P<0.05). Levels of sOC, uNTx and uZn decreased about 40, 46 and 37%, respectively, in calcitonin group at 6 months after the start of treatment. CONCLUSIONS: Our study suggests that values of uNTx, uZn and sOC were significantly lower in the patient group than those in control group and in postmenopausal women with osteopororsis, calcitonin reduces the concentrations of uNTx, uZn and sOC. SN - 0378-5122 UR - https://www.unboundmedicine.com/medline/citation/15978968/The_effect_of_calcitonin_on_biochemical_markers_and_zinc_excretion_in_postmenopausal_osteoporosis_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0378-5122(04)00272-5 DB - PRIME DP - Unbound Medicine ER -